Ferric carboxymaltose treatment for iron deficiency anemia in children with inflammatory bowel disease: Efficacy and risk of hypophosphatemia

Cococcioni, Lucia; Pensabene, Licia; El-Khouly, Sara; Chadokufa, S.; McCartney, Sara; Saliakellis, Efstratios; Kiparissi, F.; Borrelli, Osvaldo

doi:10.1016/j.dld.2021.02.017

Cited by 11 publications

(13 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The risk also increases with increasing age [43,77], however it may also occur in children [89][90][91][92]. The high incidence of vitamin D deficiency in the elderly [93][94][95], as well as protein-energy malnutrition, which is also a problem in the elderly [96,97], may lead to a phosphate-deficient state and explain the risk with increasing age.…”

Section: Intravenous Iron Formulationmentioning

confidence: 99%

“…FCM has been studied in children mostly retrospectively [90][91][92][151][152][153], but also prospectively [154]. FCM appeared effective in correction of anemia, with an acceptable risk profile comparable with adults.…”

Section: Practical Guidelinesmentioning

confidence: 99%

“…FCM appeared effective in correction of anemia, with an acceptable risk profile comparable with adults. Three retrospective studies reported hypophosphatemia, with incidence rates ranging from 14 to 20% [90][91][92]. To date, no studies of FDI in children have been performed and the SmPC of FDI advises it should not be used in subjects under the age of 18 years because of lack of safety data.…”

Section: Practical Guidelinesmentioning

confidence: 99%

See 2 more Smart Citations

High-Dose Intravenous Iron with Either Ferric Carboxymaltose or Ferric Derisomaltose: A Benefit-Risk Assessment

Boots

Quax

2022

Drug Saf

View full text Add to dashboard Cite

The intravenous iron formulations ferric carboxymaltose (FCM) and ferric derisomaltose (FDI) offer the possibility of administering a large amount of iron in one infusion. This results in faster correction of anemia and the formulations being better tolerated than oral iron formulations. This triad of logistic advantages, improved patient convenience, and fast correction of anemia explains the fact that intravenous iron formulations nowadays are frequently prescribed worldwide in the treatment of iron deficiency anemia. However, these formulations may result in hypophosphatemia by inducing a strong increase in active fibroblast growth factor-23 (FGF-23), a hormone that stimulates renal phosphate excretion. This effect is much more pronounced with FCM than with FDI, and therefore the risk of developing hypophosphatemia is remarkably higher with FCM than with FDI. Repeated use of FCM may result in severe osteomalacia, which is characterized by bone pain, Looser zones (pseudofractures), and low-trauma fractures. Intravenous iron preparations are also associated with other adverse effects, of which hypersensitivity reactions are the most important and are usually the result of a non-allergic complement activation on nanoparticles of free labile iron—Complement Activation-Related Pseudo-Allergy (CARPA). The risk on these hypersensitivity reactions can be reduced by choosing a slow infusion rate. Severe hypersensitivity reactions were reported in < 1% of prospective trials and the incidence seems comparable between the two formulations. A practical guideline has been developed based on baseline serum phosphate concentrations and predisposing risk factors, derived from published cases and risk factor analyses from trials, in order to establish the safe use of these formulations.

show abstract

Section: Intravenous Iron Formulationmentioning

confidence: 99%

Section: Practical Guidelinesmentioning

confidence: 99%

Section: Practical Guidelinesmentioning

confidence: 99%

See 1 more Smart Citation

High-Dose Intravenous Iron with Either Ferric Carboxymaltose or Ferric Derisomaltose: A Benefit-Risk Assessment

Boots

Quax

2022

Drug Saf

View full text Add to dashboard Cite

show abstract

“…4 Prevalence of iron deficiency anemia in Pakistan is 33.2% among children. 5 Micronutritional deficiency and genetic factors are the basis of pathogenesis of this condition. 6 Iron deficiency anemia leads to delay myelination of neurons especially in hippocampus, abnormality in release of neurotransmitters like Serotonin, Gamma-amino butyric acid and Dopamine and abnormal body metabolism.…”

Section: Introductionmentioning

confidence: 99%

Incidence of iron deficiency anemia among the children with febrile seizures.

Batool

Qamar

Islam

et al. 2021

TPMJ

View full text Add to dashboard Cite

Objective: To determine frequency of iron deficiency anemia among the children having febrile seizures. Study Design: Descriptive Cross Sectional study. Setting: Pediatric Unit Allama Iqbal Memorial Teaching Hospital Sialkot. Period: September 2020 to February 2021. Material & Methods: Total 70 children were studied with age six months to 10 years with either gender presenting with febrile seizures. All data of the patients was documented including demographic data like age, gender, residential area, educational status, socioeconomic status and clinical findings at the time of presentation like fever, fits and duration of symptoms etc. Blood hemoglobin and ferritin level were tested of each patient to evaluate iron deficiency anemia. Results: There were 65.7% male and 34.3% female cases in this study. Age range of the patients was 6 months to 10 years with mean age of 4.36 ± 2.71 years. Most of the children (60%) were below three years of age. Mostly children belonged to low and middle socioeconomic status with the frequency of 42.8% and 45.7% respectively. Iron deficiency anemia was found in 38.6% cases. Majority of the mothers were illiterate (65%). There were 44.3% cases from rural areas and 55.7% from urban area. Conclusion: Iron deficiency anemia is a common problem among children with febrile seizures, younger than 03 years and belonging to rural areas. Illiterate mothers, is an important risk factor of iron deficiency anemia in their children.

show abstract

“…Most of the studies on IV iron therapy in the literature have been conducted in children with IBD. [5][6][7][8][9] A clear treatment recommendation cannot be made due to the heterogeneity of the study groups and the small number of comparative studies. In this study, we retrospectively evaluated children who were intolerant or unresponsive to oral therapy and therefore, treated with IV iron sucrose or ferric carboxymaltose (FCM) and compared the treatment processes and efficacy.…”

mentioning

confidence: 99%

Intravenous Iron Therapy for Children With Iron Deficiency Anemia

Orhan¹,

Büyükavcı²

2022

Journal of Pediatric Hematology/Oncology

View full text Add to dashboard Cite

Iron deficiency anemia in children is a public health problem. Although oral iron treatment is the first choice, common side effects and compliance problems can cause the treatment to be interrupted. This study retrospectively evaluated children treated with intravenous (IV) iron sucrose or ferric carboxymaltose (FCM) and compared the treatment processes and efficacy. The demographic characteristics and treatment details of the 44 children with iron deficiency anemia were retrospectively evaluated. Iron sucrose was administered to 25 patients and FCM was administered to 19 patients. The IV iron infusion was applied to 64% of the patients because of unresponsiveness to oral treatment, 25% of the patients because of compliance problems, and 11% of the patients because of severe anemia. IV iron therapy increased hemoglobin, mean corpuscular volume, mean corpuscular hemoglobin, red-cell distribution width, and serum ferritin levels and decreased platelet count. The mean number of infusions per patient in the FCM group was lower, and the total treatment time was shorter. In conclusion, IV iron sucrose or FCM can be used in children with nonadherence to oral therapy and severe anemia in addition to specific indications.

show abstract

Ferric carboxymaltose treatment for iron deficiency anemia in children with inflammatory bowel disease: Efficacy and risk of hypophosphatemia

Cited by 11 publications

References 30 publications

High-Dose Intravenous Iron with Either Ferric Carboxymaltose or Ferric Derisomaltose: A Benefit-Risk Assessment

High-Dose Intravenous Iron with Either Ferric Carboxymaltose or Ferric Derisomaltose: A Benefit-Risk Assessment

Incidence of iron deficiency anemia among the children with febrile seizures.

Intravenous Iron Therapy for Children With Iron Deficiency Anemia

Contact Info

Product

Resources

About